Pinealon

Pinealon Nasal Spray is supplied by Crystal Peptides as a catalogued research material in the specified format and strength: nasal spray, 10mg/10ml. This catalogue entry identifies the formulated product for research documentation and material selection. It does not establish suitability for a particular experimental model or imply equivalence to materials described in published studies.

Pinealon is a synthetic tripeptide with the amino-acid sequence glutamic acid–aspartic acid–arginine, conventionally written as Glu-Asp-Arg or EDR. Its research background is primarily preclinical, with interest centred on cellular oxidative-stress and cell-survival models. The identity of the peptide should be distinguished from the characteristics of the finished formulation, which also depend on its vehicle, excipients and batch-specific composition.

Chemical properties and registry information

Research background and published evidence

Published research

Published work on Pinealon is primarily preclinical and includes investigations relevant to cellular responses to oxidative stress and cell survival. Such studies provide context for research questions about the EDR tripeptide, rather than validation of this catalogue formulation. Interpretation requires attention to the original experimental system, the material tested, the formulation and the endpoints measured. No individual study result or quantitative effect is asserted in this description.

The term Pinealon alone does not establish that two research materials are interchangeable. Differences in peptide preparation, accompanying substances and experimental conditions can limit comparisons across reports. Researchers reviewing the literature should distinguish observations made with the named peptide from findings established for a specific finished product.

Current scientific understanding

The available research context is best understood as exploratory and model-dependent. Cellular oxidative-stress and cell-survival measurements address defined experimental questions; they do not by themselves establish clinical relevance, a settled mechanism or performance in another biological setting. This product description makes no claim of efficacy, potency or safety and does not present the nasal spray formulation as clinically validated.

Formulation note

Published research has mostly used other materials, preparations or routes rather than this nasal spray formulation. Findings from injected or differently formulated material cannot be transferred to this nasal spray formulation. Shared peptide identity does not establish equivalent exposure, distribution, stability or experimental behaviour. Any formulation-specific interpretation therefore requires evidence addressing the actual material under investigation, including its vehicle and excipient composition.

Quality and testing

Consult the batch-specific Certificate of Analysis (CoA) for the analytical information associated with the supplied lot, including the tests performed, methods reported and recorded results. Verify formulation and excipient details against the corresponding CoA/SDS. The catalogue strength is not a substitute for batch documentation, and unreported attributes should not be assumed. Quality documentation characterises the material within the scope of the stated testing; it does not establish biological activity or suitability for human or veterinary use.

For research use only. Not for human or veterinary use. No dosing directions are provided.